debt_leverage_profile
1.05x Total Debt / Equity (Elevated leverage)
High
SEC-XBRL
interest_rate_sensitivity
Fortress carries ~$200M+ in debt; a 200bps rate rise increases annual interest expense ~$4M, pressuring already negative EBITDA materially
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API-grade active pharmaceutical ingredients sourced from China (CMOs) and European CDMOs represent primary geopolitical chokepoints
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue; negligible sovereign currency devaluation exposure as >95% revenue is USD-denominated from US operations
Inferred
Agent_Inference
geographic_footprint
Primarily US-based operations and revenue; top markets are domestic; foreign currency devaluation risk is near-zero given <5% ex-US exposure
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single-source CMO relationships for rare-disease drugs (e.g., Coeptis, Avenue) likely exceed 30% input cost; substitution timelines are 12-24 months
Inferred
Agent_Inference
business_model_type_primary
Cloud infrastructure disruption would impair internal R&D informatics and partner portals but clinical/regulatory operations are not cloud-critical; 2-4 week recovery
Inferred
Agent_Inference
business_model_type_secondary
Secondary systems (CRM, financial reporting, partner communications) could migrate within 30 days with moderate disruption; no existential cloud dependency
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; Fortress is a biopharmaceutical holding company relying on regulatory filings, not software APIs; switching cost risk is minimal
Inferred
Agent_Inference
howey_test_risk_index
Primary revenue (royalties, product sales, licensing) does not constitute an investment contract; Howey Test risk is very low—conventional pharma commercialization
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited patient data handling; HIPAA is primary compliance burden; GDPR exposure minimal given near-zero EU operations; CCPA exposure low given B2B/institutional focus
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; Fortress holds niche rare-disease assets with small market shares; no dominant market position in any therapeutic category
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~60-70% transactional (product sales, milestones); ~30-40% recurring (royalties, licensing fees); highly lumpy and partner-dependent revenue profile
Inferred
Agent_Inference
monetization_vector
Royalty streams from partner companies (Avenue, Aevitas, etc.) plus direct product sales (Avrobio, Cypros); milestone payments create high revenue variability
Inferred
Agent_Inference
pricing_architecture
Drug pricing set by FDA-approved label and market dynamics; Fortress subsidiaries face payer/PBM price pressure; orphan drug pricing provides some insulation
Inferred
Agent_Inference
pricing_power_rating
Moderate; rare-disease orphan drugs command premium pricing, but payer pushback and biosimilar risk cap long-term pricing power at 3-5% annual increases
Inferred
Agent_Inference
target_gross_margin_bracket
Consolidated gross margin estimated 40-60%; varies widely by subsidiary; royalty income is near 100% margin while product COGS dilutes blended margin
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage problem; revenue derives from regulated drug sales and licensing agreements with contractual terms; not a platform or subscription model
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is sublinear to headcount; milestone and royalty income scales without proportional headcount; clinical-stage subsidiaries are more headcount-intensive
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of royalty/licensing revenue is near-zero; product commercialization scaling requires proportional sales force investment; blended model is partially scalable
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Fortress is a biopharmaceutical holding company with no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC would remain institutionally driven (hospital systems, specialty pharmacies); sales force efficiency improves moderately with scale
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; pharmaceutical holding model does not exhibit demand-side economies of scale or user network dynamics
Inferred
Agent_Inference
asset_efficiency_ratio
-18.1% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-high recession resistance; rare-disease drugs are non-discretionary for patients, though payer coverage decisions may tighten in downturns
Inferred
Agent_Inference
customer_segment_primary
Specialty pharmacies and hospital systems (institutional buyers) represent primary customer segment; top 3 specialty pharmacy chains likely exceed 50% of product revenue
Inferred
Agent_Inference
customer_segment_secondary
Government payers (Medicaid/Medicare) and commercial insurers as indirect revenue determinants; partner biotech companies as licensing/royalty revenue sources
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.0% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001429260
High
SEC-EDGAR
ticker
FBIO
High
SEC-EDGAR